Yes, I agree completely. Do you think it's odd that new deals haven't been announced in this space since the Medimmune deal, a) knowing what I just highlighted below, b) Antibiotics being such a hot area? Why not both these targets to many companies simultaneously? Or do you think that they've chosen to wait because they've only recently improved their technology?
Note: since the time of the CEO transcript below Phylogica have made improvements in their robotic capabilities.
"At the moment we are investing in some improvements in our robotic capabilities which will enable us to screen even larger numbers of targets in parallel to handle more than a dozen deals simultaneously."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)